BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.063x

Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) has a cash flow conversion efficiency ratio of 0.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs149.66 Million ≈ $1.62 Million USD) by net assets (Rs2.38 Billion ≈ $25.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BALAXI net asset quality score to measure how much of total assets are equity-financed.

BALAXI PHARMACEUTICALS LIMITED - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is BALAXI PHARMACEUTICALS LIMITED's earnings quality to evaluate the quality of earnings relative to operating cash generation.

BALAXI PHARMACEUTICALS LIMITED Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BALAXI PHARMACEUTICALS LIMITED ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Gold Springs Resource Corp
TO:GRC
-0.005x
FN Factory Outlet Public Company Limited
BK:FN
-0.020x
IRIDEX Corporation
NASDAQ:IRIX
0.120x
Vichitbhan Palmoil Public Company Limited
BK:VPO
-0.267x
TPC Co. Ltd
KQ:130740
0.007x
Observe Medical Asa
OL:OBSRV
-0.829x
Hotel Shilla Co Ltd
KO:008775
-0.137x
Sampann Utpadan India Limited
NSE:SAMPANN
-0.203x

Annual Cash Flow Conversion Efficiency for BALAXI PHARMACEUTICALS LIMITED (2013–2025)

The table below shows the annual cash flow conversion efficiency of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see BALAXI company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs2.32 Billion
≈ $25.06 Million
Rs-377.82 Million
≈ $-4.09 Million
-0.163x -774.66%
2024-03-31 Rs2.01 Billion
≈ $21.78 Million
Rs48.66 Million
≈ $526.25K
0.024x -27.26%
2023-03-31 Rs1.83 Billion
≈ $19.78 Million
Rs60.75 Million
≈ $657.02K
0.033x -88.99%
2022-03-31 Rs1.13 Billion
≈ $12.24 Million
Rs341.44 Million
≈ $3.69 Million
0.302x +632353.73%
2021-03-31 Rs649.80 Million
≈ $7.03 Million
Rs31.00K
≈ $335.25
0.000x +100.01%
2020-03-31 Rs277.46 Million
≈ $3.00 Million
Rs-140.62 Million
≈ $-1.52 Million
-0.507x -18.39%
2019-03-31 Rs35.21 Million
≈ $380.73K
Rs-15.07 Million
≈ $-162.98K
-0.428x +1.89%
2018-03-31 Rs15.55 Million
≈ $168.13K
Rs-6.78 Million
≈ $-73.35K
-0.436x -3.84%
2017-03-31 Rs23.59 Million
≈ $255.13K
Rs-9.91 Million
≈ $-107.20K
-0.420x +88.57%
2016-03-31 Rs314.87K
≈ $3.41K
Rs-1.16 Million
≈ $-12.52K
-3.676x -156.12%
2015-03-31 Rs322.45K
≈ $3.49K
Rs2.11 Million
≈ $22.84K
6.551x +2233.63%
2014-03-31 Rs7.80 Million
≈ $84.33K
Rs-2.39 Million
≈ $-25.89K
-0.307x -171.16%
2013-03-31 Rs7.52 Million
≈ $81.34K
Rs3.25 Million
≈ $35.09K
0.431x --

About BALAXI PHARMACEUTICALS LIMITED

NSE:BALAXI India Drug Manufacturers - Specialty & Generic
Market Cap
$14.33 Million
Rs1.32 Billion INR
Market Cap Rank
#26093 Global
#1447 in India
Share Price
Rs24.00
Change (1 day)
+0.42%
52-Week Range
Rs15.67 - Rs49.10
All Time High
Rs207.74
About

Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ve… Read more